Anti-inflammatory and immunomodulatory effects of statins

Kidney International

Volumn 63, Issue 1, 2003, Pages 12-23

  Blanco Colio, Luis Miguel ^a   Tuñón, José ^a   Martín Ventura, Jose Luis ^a   Egido, Jesús ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

Author keywords

Atherosclerosis; Blood thrombogenecity; Cardiovascular mortality; G proteins; HMG CoA reductase inhibitors; Inflammation; Lesion; Lipid lowering

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BIOCHEMICAL MARKER; CERIVASTATIN; CHOLESTEROL; COMPACTIN; FLUINDOSTATIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; LIPID; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ANGIOPLASTY; ANTIINFLAMMATORY ACTIVITY; ARTERY WALL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELLULAR DISTRIBUTION; CLINICAL TRIAL; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM LESION; HUMAN; IMMUNOMODULATION; INFLAMMATION; ISOPRENYLATION; MONOCYTE; MONONUCLEAR CELL; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; PROTEIN LOCALIZATION; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; SYNTHESIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THROMBOGENICITY;

EID: 0037213039     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00744.x     Document Type: Article

References (137)

1. Ross R: Atherosclerosis: An inflammatory disease. N Engl J Med 340:115-126, 1999
2. Falk E, Shah PK, Fuster V: Pathogenesis of plaque disruption, in Atherosclerosis and Coronary Artery Disease, edited by Fuster V, Ross R, Topol EJ, Philadelphia, Lippincott-Raven, 1996, pp 491-507
3. Davies MJ: Stability and instability: Two faces of coronary atherosclerosis. Circulation 94:2013-2020, 1996
4. Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix-metalloproteinases and matrix-degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94:2493-2503, 1994
5. Fernandez-Ortiz A, Badimon JJ, Falk E, et al: Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture. J Am Coll Cardiol 23:1562-1569, 1994
6. Toschi V, Gallo R, Lettino M, et al: Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95:594-599, 1997
7. Van der Wal AC, Becker AE, Van der Loos CM, das PK: Site of intimal rupture or erosion of thrombosed coronary athero-sclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89:36-44, 1994
8. Moreno PR, Falk E, Palacios IF, et al: Macrophage infiltration in acute coronary syndromes: Implication for plaque rupture. Circulation 90:775-778, 1994
9. Henney AM, Wakeley PR, Davies MJ, et al: Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridazation. Proc Natl Acad Sci USA 88:8154-8158, 1991
10. Li Z, Li L, Zielke HR, et al: Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol 148:121-128, 1996
11. Sukhova GK, Schönbeck U, Rabkin E, et al: Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 99:2503-2509, 1999
12. Biasucci LM, Liuzzo G, Grillo RL, et al: Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 99:855-860, 1999
13. Ridker PM, Cushman M, Stampfer MJ, et al: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 326:973-979, 1997
14. Ridker PM, Rifai N, Clearfield M, et al: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344:1959-1965, 2001
15. Liuzzo G, Biasucci LM, Gallimore JR, et al: The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331:417-424, 1994
16. Mendall MA, Patel P, Ballam L, et al: C reactive protein and its relation to cardiovascular risk factor: A population based cross sectional study. BJM 312:1061-1065, 1996
17. Hernández-Presa MA, Ortego M, Tuñón J, et al: Simvastatin reduces inflammation in rabbit atheroma more markedly than dietary lipid lowering. Cardiovasc Res (in press)
18. Hernández-Presa MA, Bustos C, Ortego M, et al: Angiotensin converting enzyme inhibition prevents arterial NF-κB activation, MCP-1 expression and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 95:1532-1541, 1997
19. Hernández-Presa MA, Bustos C, Ortego M, et al: The ACE inhibitor quinapril reduces the arterial expression of NF-κB dependent proinflammatory factors but not of collagen in a rabbit model of atherosclerosis. Am J Pathol 153:1825-1837, 1998
20. Bustos C, Hernández-Presa MA, Ortego M, et al: HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 32:2057-2064, 1998
21. Blanco-Colio LM, Valderrama M, Alvarez-Sala LA, et al: Red wine intake prevents nuclear factor-kappaB activation in peripheral blood mononuclear cells of healthy volunteers during postprandial lipemia. Circulation 102:1020-1026, 2000
22. The 4S Investigators: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994
23. Brown BG, Fuster V: Impact of management in stabilization of coronary disease, in Atherosclerosis and Coronary Artery Disease, edited by Fuster V, Ross R, Topol EJ, Philadelphia, Lippincott-Raven, 1996, pp 191-205
24. Schwartz GG, Olsson AG, Ezekowitz MD, et al: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. JAMA 285: 1711-1718, 2001
25. O'Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-CoA reductase inhibitor, improves endothelial function within 1 month. Circulation 95:1126-1131, 1997
26. Dangas G, Badimon JJ, Smith DA, et al: Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 33:1294-1304, 1999
27. Andrews TC, Raby K, Barry J, et al: Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 95:324-328, 1997
28. Newby DE, Wright RA, Labinjoh C, et al: Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking. Circulation 99:1411-1415, 1999
29. Panza JA, Garcia CE, Kilcoyne CM, et al: Impaired endothelium-dependent vasodilation in patients with essential hypertension: Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 91:1732-1738, 1995
30. Kawano H, Motoyama T, Hirashima O, et al: Hyperglycemia rapidly supresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 34:146-154, 1999
31. Lewis TV, Dart AM, Chin-dusting JPF: Endothelium-dependent relaxation by acetylcholine is impaired in hypertriglyceridemic humans with normal levels of plasma LDL cholesterol. J Am Coll Cardiol 33:805-812, 1999
32. Niwa S, Totsuka T, Hayashi S: Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol 18:669-675, 1996
33. Takeuchi S, Kawashima S, Rikitake Y, et al: Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC. Biochem Biophys Res Commun 269:97-102, 2000
34. Weber C, Erl W, Weber KS, Weber PC: HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 30:1212-1217, 1997
35. Kimura M, Kurose I, Russell J, Granger DN: Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol 17:1521-1526, 1997
36. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7:687-692, 2001
37. Seljeflot I, Tonstad S, Hjermann I, Arnesen H: Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis 162:179-185, 2002
38. Hernández-Presa MA, Martín-Ventura JL, Ortego M, et al: Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis 160:147-153, 2002
39. Grimm S, Baeuerle PA: The inducible transcription factor NF-κB: Structure-function relationship of its protein subunits. Biochem J 290:297-308, 1993
40. Henkel T, Machleidt T, Alkalay I, et al: Rapid proteolysis of IκB-κ is necessary for activation of transcription factor NF-κB. Nature 365:182-185, 1993
41. Barnes PJ, Karin M: Nuclear factor-κB. A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071, 1997
42. Egido J, Hernández-Presa MA, Tuñó J, et al: Transcription factor κB (NF-κB) and cardiovascular disease. Cardiovasc Risk Factors 9:159-168, 1999
43. Brand K, Page S, Walli AK, et al: Role of nuclear factor-kappa B in atherogenesis. Exp Physiol 82:297-304, 1997
44. Bourcier T, Sukhova G, Libby P: The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem 272:15817-15824, 1997
45. Brand K, Page S, Bartsch A, et al: Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 97:1715-1722, 1996
46. Wilson SH, Best PJ, Edwards WD, et al: Nuclear factor-kappaB immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectoris. Atherosclerosis 160:147-153, 2002
47. Simon LS: Role and regulation of cyclooxygenase-2 during inflammation. Am J Med 106:37S-42S, 1999
48. Schönbeck U, Sukhove GK, Graber P, et al: Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155:1281-1291, 1999
49. Cipollone F, Prontera C, Pini B, et al: Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 104:921-927, 2001
50. Shiomi M, Ito T: Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits. Br J Pharmacol 126:961-968, 1999
51. Aikawa M, Rabkin E, Sugiyama S, et al: An HMG-CoA reductase inhibitor, cerivastatin, supresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103:276-283, 2001
52. Fukumoto Y, Libby P, Rabkin E, et al: Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 103:993-999, 2001
53. Bellosta S, Via D, Canavesi M, et al: HMG-Coa reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18:1671-1678, 1998
54. Crisby M, Nordin-Fredriksson G, Shah PK, et al: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 103:926-933, 2001
55. Baumann H, Gauldie J: The acute phase response. Immunol Today 15:74-80, 1994
56. Musial J, Undas A, Gajewski P, et al: Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 77:247-253, 2001
57. Ridker PM, Rifai N, Lowental SP: Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 103:1191-1193, 2001
58. Jialal I, Stein D, Balis D, et al: Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103:1933-1935, 2001
59. Gómez-Gerique JA, Ros E, Olivan J, et al: Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis 162:245-251, 2002
60. Chang JW, Yang WS, Min WK, et al: Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 39:1213-1217, 2002
61. Biasucci LM, Liuzzo G, Grillo RL, et al: Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 99:855-860, 1999
62. Ridker PM, Rifai N, Pfeffer MA, et al: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98:839-844, 1998
63. De Lemos JA, Hennekens CH, Ridker PM: Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. J Am Coll Cardiol 36:423-426, 2000
64. Iadecola C, Alexander M: Cerebral ischemia and inflammation. Curr Opin Neurol 14:89-94, 2001
65. Ridker PM, Hennekens CH, Roitman-Johnson B, et al: Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 351:88-92, 1998
66. Hackman A, Abe Y, Insull WJR, et al: Levels of soluble cell adhesion in patients with dyslipidemia. Circulation 93:1334-1338, 1996
67. Kai H, Ikeda H, Yasukawa H, et al: Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32:368-372, 1998
68. Kalela A, Laaksonen R, Lehtimaki T, et al: Effect of pravastatin in mildly hypercholesterolemic young men on serum matrix metalloproteinases. Am J Cardiol 88:173-175, 2001
69. Solheim S, Seljeflot I, Arnesen H, et al: Reduces levels of TNF alpha in hypercholesterolemic individuals after treatment with pravastatin for 8 weeks. Atherosclerosis 157:411-415, 2001
70. Ferro D, Violi F: Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 36:427-431, 2000
71. Ritchie ME: Nuclear factor-κB is selectively and markedly activated in humans with unstable angina pectoris. Circulation 98:1707-1713, 1998
72. Berberian PA, Myers W, Tytell M, et al: Immunohistochemical localization of heat shock protein-70 in normal-appearing and atherosclerotic specimens of human arteries. Am J Pathol 136:71-80, 1990
73. O'Brien KD, Alpers CE, Hokanson JE, et al: Oxidation-specific epitopes in human coronary atherosclerosis are not limited to oxidized low-density lipoprotein. Circulation 94:1216-1225, 1996
74. Stemme S, Faber B, Holm J, et al: T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 92:3893-3897, 1995
75. Caligiuri G, Liuzzo G, Biasucci LM, Maseri A: Immune system activation follows inflammation in unstable angina: Pathogenetic implications. J Am Coll Cardiol 32:1295-1304, 1998
76. Neri Serneri GG, Prisco D, Martini F, et al: Acute T-cell activation is detectable in unstable angina. Circulation 95:1806-1812, 1997
77. Farb A, Burke AP, Tang AL, et al: Coronary plaque erosion without rupture into a lipid core: A frequent cause of coronary thrombosis in sudden coronary death. Circulation 93:1354-1363, 1996
78. Arbustini E, De Servi S, Bramucci E, et al: Comparison of coronary lesions obtained by directional coronary atherectomy in unstable angina, stable angina, and restenosis after either atherectomy or angioplasty. Am J Cardiol 75:675-682, 1995
79. Liuzzo G, Vallejo AN, Kopecky SL, et al: Molecular fingerprint of interferon-gamma signaling in unstable angina. Circulation 103:1509-1514, 2001
80. Serneri GG, Abbate R, Gori AM, et al: Transient intermittent lymphocyte activation is responsible for the instability of angina. Circulation 86:790-797, 1992
81. Cuthbert JA, Lipsky PE: Sterol metabolism and lymphocyte responsiveness: Inhibition of endogenous sterol synthesis prevents mitogen-induced human T cell proliferation. J Immunol 126:2093-2099, 1981
82. Cutts JL, Bankhurst AD: Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lovastatin. Int J Immunopharmacol 11:863-869, 1989
83. Kurakata S, Kada M, Shimada Y, et al: Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology 34:51-61, 1996
84. Kwak B, Mulhaupt F, Myit S, Mach F: Statins as a newly recognized type of immunomodulator. Nat Med 6:1399-1402, 2000
85. Steimle V, Siegrist CA, Mottet A, et al: Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 265:106-109, 1994
86. Palinski W: Immunomodulation: A new role for statins? Nat Med 12:1311-1312, 2000
87. Muldom MF, Flory JD, Marsland A, et al: Effects of lovastatin on the immune system. Am J Cardiol 80:1391-1394, 1997
88. Kobashigawa JA, Katznelson S, Laks H, et al: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333:621-627, 1995
89. Wenke K, Meiser B, Thiery J, et al: Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial. Circulation 96:1398-1402, 1997
90. Katznelson S, Wilkinson AH, Kobashigawa JA, et al: The effect of pravastatin on acute rejection after kidney transplantation - A pilot study. Transplantation 61:1469-1474, 1996
91. Holdaas H, Jardine AG, Wheeler DC, et al: Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial. Kidney Int 60:1990-1997, 2001
92. Kasiske BL, Heim-Duthoy KL, SINGER GG, et al: The effects of lipid-lowering agents on acute renal allograft rejection. Transplantation 72:223-227, 2001
93. Sahu K, Sharma R, Gupta A, et al: Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection. Clin Transplant 15:173-175, 2001
94. Holdaas H, Fellstrom B, Holme I, et al: Effects of fluvastatin on cardiac events in renal transplant patients. ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. J Cardiovasc Risk 8:63-71, 2001
95. Garlichs CD, John S, Schmeisser A, et al: Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 104:2395-2400, 2001
96. Schonbeck U, Libby P: CD40 signaling and plaque instability. Circ Res 89:1092-1103, 2001
97. Garlichs CD, Eskafis, Raaz D, et al: Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 86:649-655, 2001
98. Aukrust P, Muller F, Ueland T, et al: Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100:614-620, 1999
99. Schonbeck U, Varo N, Libby P, et al: Soluble CD40L and cardiovascular risk in women. Circulation 104:2266-2268, 2001
100. Liao F, Andalibi A, De Beer FC, et al: Genetic control of inflammatory gene induction and NF-κB-like transcription factor activation in response to atherogenic diet in mice. J Clin Invest 91:2572-2579, 1993
101. Xu XP, Meisel SR, Ong JM, et al: Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 99:993-998, 1999
102. Sakata-Kaneko S, Wakatsuki Y, Usui T, et al: Lysophosphatidylcholine upregulates CD40 ligand expression in newly activated human CD4+ T cells. FEBS Lett 433:161-165, 1998
103. Aikawa M, Voglic SJ, Sugiyama S, et al: Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation 100:1215-1222, 1999
104. Aikawa M, Rabkin E, Okada Y, et al: Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma. Circulation 97:2433-2444, 1998
105. West of scotland coronary prevention study group: Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97:1440-1445, 1998
106. Williams JK, Sukhova GK, Herrington DM, Libby P: Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 31:684-691, 1998
107. Sparrow CP, Burton CA, Hernandez M, et al: Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 21:115-121, 2001
108. Pruefer D, Scalia R, Lefer AM: Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol 19:2894-2900, 1999
109. Scalia R, Gooszen ME, Jones SP, et al: Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation 103:2598-2603, 2001
110. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 343:425-430, 1990
111. Van Aelst L, D'souza-Schorey C: Rho GTPases and signaling networks. Genes Dev 11:2295-2322, 1997
112. Blanco-Colio LM, Villa A, Ortego M, et al: 3-Hydroxy-3-methyl-glutaryl Coenzyme A reductase inhibitors atorvastatin and simvastatin induce apoptosis in vascular smooth muscle cells by downregulation of Bcl-2 expression and RhoA prenylation. Atherosclerosis 161:17-26, 2002
113. Mackay DJ, Hall A: Rho GTPases. J Biol Chem 273:20685-20688, 1998
114. Zohn IM, Campbell SL, Khosravi-Far R, et al: Rho family proteins and Ras transformation: The RHOad less traveled gets congested. Oncogene 17:1415-1438, 1998
115. Takemoto M, Liao J: Pleiotropic effects of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Arterioscler Thromb Vasc Biol 21:1712-1719, 2001
116. Ortego M, Bustos B, Hernández-Presa MA, et al: Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 147:253-261, 1999
117. Inoue I, Goto S, Mizotani K, et al: Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of mRNA levels for interleukin-1β, interleukin-6, cyclooxygenase 2, and p22phox by regulation of peroxisome proliferator-activated receptor-α(PPAR-α) in primary endothelial cells. Life Sci 67:863-876, 2000
118. Vrtovsnik F, Coutte S, Prie D, et al: Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway. Kidney Int 52:1016-1027, 1997
119. Ortego M, Gomez-Hernandez A, Bustos C, et al: 3-Hydroxy-3-methyl-glutaryl coenzyme a reductase inhibitors increase the binding activity and nuclear level of Oct-1 in mononuclear cells. Eur J Pharmacol 448:113-121, 2002
120. Laufs U, Marra D, Node K, Liao JK: 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced downregulation of p27(Kip1). J Biol Chem 274:21926-21931, 1999
121. Corsini A, Mazzotti M, Raiteri M, et al: Relationship between mevalonate pathway and arterial myocyte proliferation: In vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 101:117-125, 1993
122. Soma MR, Donetti E, Parolini C, et al: HMG-CoA reductase inhibitors: In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb 13:571-578, 1993
123. Corsini A, Pazzucconi F, Arnaboldi L, et al: Direct effects of statins on the vascular wall. J Cardiovasc Pharmacol 31:773-778, 1998
124. Guijarro C, Blanco-Colio LM, Ortego M, et al: 3-Hydroxy-3-methy-glutaryl coenzyme A redcurase and isoprenylation inhibitors induce apoptosis in vascular smooth muscle cells in culture. Circ Res 83:490-500, 1998
125. Buemi M, Allegra A, Senatore M, et al: Pro-apoptotic effect of fluvastatin on human vascular smooth muscle cells. Eur J Pharmacol 370:201-203, 1999
126. Bourcier T, Libby P: HMG-CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 20:556-562, 2000
127. Ichiki T, Takeda K, Tokunou T, et al: Dowregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 21:1896-1901, 2001
128. Fischman DL, Leon MB, Baim DS, et al: A randomizad comparison of coronarystent placement and ballon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N Engl J Med 331:496-501, 1994
129. Hoffmann R, Mintz GS, Dussaillant GR, et al: Patterns and mechanisms of instent restenosis. Circulation 94:1247-1254, 1996
130. Weintraub WS, Bocuzzi SJ, Klein JL, et al: Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. N Engl J Med 331:1331-1337, 1994
131. Bertrand ME, Mcfadden EP, Fruchart JF, et al: Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. J Am Coll Cardiol 30:863-869, 1997
132. Serruys PW, Foley DP, Jackson G, et al: A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the Fluvastatin Angiographic Restenosis (FLARE) trial. Eur Heart J 20:58-69, 1999
133. Serruys PW, De Feyter P, Macaya C, et al: Fluvastatin for prevention of cardiac events following successful first percutaneous intervention. JAMA 287:3215-3222, 2002
134. Walter DH, Fichtlscherer S, Britten MB, et al: Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol 38:2006-2012, 2001
135. Meuwissen M, Piek JJ, Vander WAL AC, et al: Recurrent unstable angina after directional coronary atherectomy is related to the extent of initial coronary plaque inflammation. J Am Coll Cardiol 37:1271-1276, 2001
136. Morice MC, Serruys PW, Sousa JE, et al: A randomized comparison of a sirolimuseluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773-1780, 2002
137. Rosenson RR, Tangney CC: Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. JAMA 279:1643-1650, 1998